Neurocognitive costs and benefits of psychotropic medications in older adults

Journal of Geriatric Psychiatry and Neurology

Volumn 20, Issue 4, 2007, Pages 199-214

  Brooks III, John O ^a,b   Hoblyn, Jennifer C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Adverse effects; Attention; Cognition disorders; Elderly; Memory; Psychopharmacology

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOZAPINE; DOSULEPIN; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE MALEATE; HALOPERIDOL; HYPNOTIC AGENT; IMIPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; ATTENTION; ATTENTION DISTURBANCE; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COST BENEFIT ANALYSIS; DELIRIUM; DEPRESSION; DROWSINESS; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; KORSAKOFF PSYCHOSIS; LETHARGY; LOW DRUG DOSE; MAJOR DEPRESSION; MEMORY; MEMORY DISORDER; MENTAL DISEASE; MENTAL FUNCTION; MENTAL PATIENT; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RECALL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; VERBAL MEMORY; VISUAL MEMORY;

AGE FACTORS; AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ATTENTION; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; CONTROLLED CLINICAL TRIALS AS TOPIC; DEMENTIA; HUMANS; HYPNOTICS AND SEDATIVES; METABOLIC CLEARANCE RATE; PSYCHOTROPIC DRUGS; RISK FACTORS;

EID: 35948930549     PISSN: 08919887     EISSN: 15525708     Source Type: Journal    
DOI: 10.1177/0891988707308803     Document Type: Review

References (221)

1. Liu IY, LaCroix AZ, White LR et al. Cognitive impairment and mortality: a study of possible confounders. Am J Epidemiol. 1990 ; 132 (1). 136-143.
2. Deeg DJ, Hofman A., van Zonneveld RJ. The association between change in cognitive function and longevity in Dutch elderly. Am J Epidemiol. 1990 ; 132 (5). 973-982.
3. Craig D., Passmore AP, Fullerton KJ, et al. Factors influencing prescription of CNS medications in different elderly populations. Pharmacoepidemiol Drug Saf. 2003 ; 12 (5). 383-387.
4. Berg S., Dellasega C. The use of psychoactive medications and cognitive function in older adults. J Aging Health. 1996 ; 8 (1). 136-149.
5. Holmberg G. Critical flicker fusion (CFF) test for sedative effect of antidepressants. Acta Psychiatr Scand Suppl. 1981 ; 290: 289-301.
6. Settle EC Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry. 1998 ; 59 (suppl 16). 25-30, 40-42.
7. Reynolds CF, Perel JM, Kupfer DJ, et al. Open-trial response to antidepressant treatment in elderly patients with mixed depression and cognitive impairment. Psychiatry Res. 1987 ; 21 (2). 111-122.
8. Branconnier RJ, Cole JO, Ghazvinian S., Rosenthal S. Treating the depressed elderly patient: the comparative behavioral pharmacology of mianserin and amitriptyline. In: Typical and Atypical Antidepressants: Clinical Practice. New York, NY: Raven Press ; 1982.
9. Meyers BS, Mattis S., Gabriele M., Kakuma T. Effects of nortriptyline on memory self-assessment and performance in recovered elderly depressives. Psychopharmacol Bull. 1991 ; 27 (3). 295-299.
10. Teri L., Reifler BV, Veith RC, et al. Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol. 1991 ; 46 (6). P372 - P377.
11. Taragano FE, Lyketsos CG, Mangone CA, et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics. 1997 ; 38 (3). 246-252.
12. Hoff AL, Shukla S., Helms P., et al. The effects of nortriptyline on cognition in elderly depressed patients. J Clin Psychopharmacol. 1990 ; 10 (3). 231-232.
13. Knegtering H., Eijck M., Huijsman A. Effects of antidepressants on cognitive functioning of elderly patients: a review. Drugs Aging. 1994 ; 5 (3). 192-199.
14. Kumar S., Kulkarni SK Influence of antidepressant drugs on learning and memory paradigms in mice. Indian J Exp Biol. 1996 ; 34 (5). 431-435.
15. Georgotas A., McCue RE, Reisberg B., et al. The effects of mood changes and antidepressants on the cognitive capacity of elderly depressed patients. Int Psychogeriatr. 1989 ; 1 (2). 135-143.
16. Podewils LJ, Lyketsos CG Tricyclic antidepressants and cognitive decline. Psychosomatics. 2002 ; 43 (1). 31-35.
17. Rocca P., Calvarese P., Faggiano F., et al. Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. J Clin Psychiatry. 2005 ; 66 (3). 360-369.
18. Caballero J., Hitchcock M., Scharre D., et al. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study. Clin Ther. 2006 ; 28 (10). 1695-1700.
19. Finkel SI, Richter EM, Clary CM, Batzar E. Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am J Geriatr Psychiatry. 1999 ; 7 (3). 221-227.
20. Newhouse PA, Krishnan KR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry. 2000 ; 61 (8). 559-568.
21. Schöne W., Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1993 ; 13 (6 )(suppl 2). 34S - 39S.
22. Oxman TE Antidepressants and cognitive impairment in the elderly. J Clin Psychiatry. 1996 ; 57 (suppl 5). 38-44.
23. Cassano GB, Puca F., Scapicchio PL, et al. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry. 2002 ; 63 (5). 396-402.
24. Doraiswamy PM, Krishnan KR, Oxman T., et al. Does antidepressant therapy improve cognition in elderly depressed patients? J Gerontol A Biol Sci Med Sci. 2003 ; 58 (12). M1137 - M1144.
25. Folstein MF, Folstein SE, McHugh PR " Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 ; 12 (3). 189-198.
26. Mowla A., Mosavinasab M., Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol. 2007 ; 27 (1). 67-70.
27. Martin PR, Adinoff B., Lane E., et al. Fluvoxamine treatment of alcoholic amnestic disorder. Eur Neuropsychopharmacol. 1995 ; 5 (1). 27-33.
28. Martin PR, Adinoff B, Eckardt, et al. Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine: preliminary findings. Arch Gen Psychiatry. 1989 ; 46 (7). 617-621.
29. Stapleton JM, Eckardt M.J., Martin P., et al. Treatment of alcoholic organic brain syndrome with the serotonin reuptake inhibitor fluvoxamine: a preliminary study. Adv Alcohol Subst Abuse. 1988 ; 7 (3-4). 47-51.
30. Hasbroucq T., Rihet P., Blin O., Possamai CA Serotonin and human information processing: fluvoxamine can improve reaction time performance. Neurosci Lett. 1997 ; 229 (3). 204-208.
31. Fairweather DB, Ashford J., Hindmarch I. Effects of fluvoxamine and dothiepin on psychomotor abilities in healthy volunteers. Pharmacol Biochem Behav. 1996 ; 53 (2). 265-269.
32. Kerr JS, Fairweather DB, Mahendran R., Hindmarch I. The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. Int Clin Psychopharmacol. 1992 ; 7 (2). 101-108.
33. Geretsegger C., Böhmer F., Ludwig M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol. 1994 ; 9 (1). 25-29.
34. Nebes RD, Pollock BG, Mulsant BH, et al. Cognitive effects of paroxetine in older depressed patients. J Clin Psychiatry. 1999 ; 60 (suppl 20). 26-29.
35. Nebes RD, Pollock BG, Houck PR, et al. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res. 2003 ; 37 (2). 99-108.
36. Devanand DP, Pelton GH, Marston K., et al. Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry. 2003 ; 18 (2). 123-130.
37. Munro CA, Brandt J., Sheppard JM, et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the Depression in Alzheimer's Disease Study (DIADS). Am J Geriatr Psychiatry. 2004 ; 12 (5). 491-498.
38. Constant EL, Adam S., Gillain B., et al. Effects of sertraline on depressive symptoms and attentional and executive functions in major depression. Depress Anxiety. 2005 ; 21 (2). 78-89.
39. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001 ; 25 (6). 871-880.
40. Trick L., Stanley N., Rigney U., Hindmarch I. A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.i.d.) venlafaxine and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression being treated in general practice. J Psychopharmacol. 2004 ; 18 (2). 205-214.
41. Nathan PJ, Sitaram G., Stough C., et al. Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Behav Pharmacol. 2000 ; 11 (7-8). 639-642.
42. Somerset Pharmaceuticals, Inc. EMSAM Data Sheet. Tampa, FL: Somerset Pharmaceuticals Inc ; 2006.
43. Wilcock GK, Birks J., Whitehead A., Evans SJ The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int J Geriatr Psychiatry. 2002 ; 17 (2). 175-183.
44. Sennef C., Timmer CJ, Sitsen JM Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol. 2003 ; 18 (2). 91-101.
45. Burns M., Moskowitz H., Jaffe J. A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. J Clin Psychiatry. 1986 ; 47 (5). 252-254.
46. Branconnier RJ, Cole JO, Ghazvinian S., et al. Clinical pharmacology of bupropion and imipramine in elderly depressives. J Clin Psychiatry. 1983 ; 44 (5, pt 2). 130-133.
47. Ferguson HB, Simeon JG Evaluating drug effects on children's cognitive functioning. Prog Neuropsychopharmacol Biol Psychiatry. 1984 ; 8 (4-6). 683-686.
48. Gobbi G., Slater S., Boucher N., et al. Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol. 2003 ; 23 (3). 233-239.
49. Trivedi MH, Kleiber BA Algorithm for the treatment of chronic depression. J Clin Psychiatry. 2001 ; 62 (suppl 6). 22-29.
50. Stahl SM Essential Psychopharmacology. Cambridge, England: Cambridge University Press ; 2000.
51. Burton LC, German PS, Rovner BW, Brant LJ Physical restraint use and cognitive decline among nursing home residents. J Am Geriatr Soc. 1992 ; 40 (8). 811-816.
52. Woerner MG, Alvir JM, Kane JM, et al. Neuroleptic treatment of elderly patients. Psychopharmacol Bull. 1995 ; 31 (2). 333-337.
53. Devanand DP, Sackeim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol. 1989 ; 46 (8). 854-857.
54. McShane R., Keene J., Gedling K., et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997 ; 314 (7076). 266-270.
55. Brown JW, Chobor A., Zinn F. Dementia testing in the elderly. J Nerv Ment Dis. 1993 ; 181 (11). 695-698.
56. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry. 2002 ; 51 (12). 972-978.
57. Bilder RM, Goldman RS, Volavka J., et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002 ; 159 (6). 1018-1028.
58. Woodward ND, Purdon SE, Meltzer HY, Zald DH A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005 ; 8 (3). 457-472.
59. Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl). 2006 ; 187 (3). 312-320.
60. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999 ; 340 (10). 757-763.
61. Lee MA, Thompson PA, Meltzer HY Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 1994 ; 55 (suppl B): 82-87.
62. Galletly CA, Clark CR, McFarlane AC, Weber DL The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2000 ; 24 (8). 1329-1338.
63. Gallhofer B., Bauer U., Lis S., et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol. 1996 ; 6 (suppl 2). S13 - S20.
64. Goldberg TE, Greenberg RD, Griffin SJ, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 1993 ; 162: 43-48.
65. Weiser M., Shneider-Beeri M., Nakash N., et al. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS? Schizophr Res. 2000 ; 46 (2-3). 81-89.
66. Fujii DE, Ahmed I., Jokumsen M., Compton JM The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci. 1997 ; 9 (2). 240-245.
67. Bender S., Dittmann-Balcar A., Schall U., et al. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol. 2006 ; 9 (2). 135-145.
68. Hou Y., Wu CF, Yang JY, Guo T. Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30 (8). 1486-1495.
69. Beuzen JN, Taylor N., Wesnes K., Wood A. A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. J Psychopharmacol. 1999 ; 13 (2). 152-158.
70. Meltzer HY, McGurk SR The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999 ; 25 (2). 233-255.
71. Sharma T., Hughes C., Soni W., Kumari V. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology (Berl). 2003 ; 169 (3-4). 398-403.
72. McGurk SR, Lee MA, Jayathilake K., Meltzer HY Cognitive effects of olanzapine treatment in schizophrenia. MedGenMed. 2004 ; 6 (2). e27.
73. Kennedy J., Deberdt W., Siegal A., et al. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Int J Geriatr Psychiatry. 2005 ; 20 (11). 1020-1027.
74. Purdon SE, Jones BD, Stip E.,, et al. Canadian Collaborative Group for Research in Schizophrenia. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry. 2000 ; 57 (3). 249-258.
75. Harvey PD, Bowie CR, Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci. 2006 ; 18 (1). 54-63.
76. Harvey PD, Napolitano JA, Mao L., Gharabawi G. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry. 2003 ; 18 (9). 820-829.
77. Purdon SE, Malla A., Labelle A., Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001 ; 26 (2). 137-149.
78. Velligan DI, Newcomer J., Pultz J., et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res. 2002 ; 53 (3). 239-248.
79. Scharre DW, Chang SI Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2002 ; 16 (2). 128-130.
80. Rossi A., Mancini F., Stratta P., et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand. 1997 ; 95 (1). 40-43.
81. Harvey PD, Rabinowitz J., Eerdekens M., Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005 ; 162 (10). 1888-1895.
82. Rémillard S., Pourcher E., Cohen H. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophr Res. 2005 ; 80 (1). 99-106.
83. Barkić J., Filaković P., Radanović-Grgurić L., et al. The influence of risperidone on cognitive functions in schizophrenia. Coll Antropol. 2003 ; 27 (suppl 1). 111-118.
84. Akdede BB, Anil Yaǧcioǧlu AE, Alptekin K., et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry. 2006 ; 67 (12). 1912-1919.
85. Harvey PD, Meltzer H., Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004 ; 66 (2-3). 101-113.
86. Malhotra AK, Burdick KE, Razi K., et al. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity? Schizophr Res. 2006 ; 87 (1-3). 181-184.
87. Schneider LS, Dagerman K., Insel PS Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006 ; 14 (3). 191-210.
88. Ellingrod VL, Schultz SK, Ekstam-Smith K., et al. Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy. 2002 ; 22 (1). 1-5.
89. Goldberg JF, Burdick KE Cognitive side effects of anticonvulsants. J Clin Psychiatry. 2001 ; 62 (suppl 14). 27-33.
90. Duncan JS, Shorvon SD, Trimble MR Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia. 1990 ; 31 (5). 584-591.
91. Gillham RA, Williams N., Wiedmann KD, et al. Cognitive function in adult epileptic patients established on anticonvulsant monotherapy. Epilepsy Res. 1990 ; 7 (3). 219-225.
92. Prevey ML, Delaney RC, Cramer JA,, et al. Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Effect of valproate on cognitive functioning: comparison with carbamazepine. Arch Neurol. 1996 ; 53 (10). 1008-1016.
93. Aikiä M., Jutila L., Salmenperä T., et al. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies. Epilepsia. 2006 ; 47 (7). 1121-1127.
94. Read CL, Stephen LJ, Stolarek IH, et al. Cognitive effects of anticonvulsant monotherapy in elderly patients: a placebo-controlled study. Seizure. 1998 ; 7 (2). 159-162.
95. Hessen E., Lossius MI, Reinvang I., Gjerstad L. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia. 2006 ; 47 (12). 2038-2045.
96. Khan A., Ginsberg LD, Asnis GM, et al. Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. J Clin Psychiatry. 2004 ; 65 (11). 1483-1490.
97. Gillham R., Kane K., Bryant-Comstock L., Brodie MJ A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure. 2000 ; 9 (6). 375-379.
98. Martin R., Kuzniecky R., Ho S., et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999 ; 52 (2). 321-327.
99. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology. 2001 ; 56 (9). 1177-1182.
100. Daban C., Martínez-Arán A., Torrent C., et al. Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. J Clin Psychopharmacol. 2006 ; 26 (2). 178-181.
101. Judd LL, Hubbard B., Janowsky DS, et al. The effect of lithium carbonate on the cognitive functions of normal subjects. Arch Gen Psychiatry. 1977 ; 34 (3). 355-357.
102. Squire LR, Judd LL, Janowsky DS, Huey LY Effects of lithium carbonate on memory and other cognitive functions. Am J Psychiatry. 1980 ; 137 (9). 1042-1046.
103. Glue PW, Nutt DJ, Cowen PJ, Broadbent D. Selective effect of lithium on cognitive performance in man. Psychopharmacology (Berl). 1987 ; 91 (1). 109-111.
104. Pachet AK, Wisniewski AM The effects of lithium on cognition: an updated review. Psychopharmacology (Berl). 2003 ; 170 (3). 225-234.
105. Ananth J., Ghadirian AM, Engelsmann F. Lithium and memory: a review. Can J Psychiatry. 1987 ; 32 (4). 312-316.
106. Kocsis JH, Shaw ED, Stokes PE, et al. Neuropsychologic effects of lithium discontinuation. J Clin Psychopharmacol. 1993 ; 13 (4). 268-275.
107. Mecarelli O., Vicenzini E., Pulitano P., et al. Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. Ann Pharmacother. 2004 ; 38 (11). 1816-1822.
108. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol. 1993 ; 44 (6). 529-533.
109. Aikiä M., Kälviäinen R., Sivenius J., et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res. 1992 ; 11 (3). 199-203.
110. McKee PJ, Blacklaw J., Forrest G., et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol. 1994 ; 37 (1). 27-32.
111. Brunbech L., Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs. 2002 ; 62 (4). 593-604.
112. Fritz N., Glogau S., Hoffmann J., et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav. 2005 ; 6 (3). 373-381.
113. Kockelmann E., Elger CE, Helmstaedter C. Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy Behav. 2004 ; 5 (5). 716-721.
114. Meador KJ, Loring DW, Vahle VJ, et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology. 2005 ; 64 (12). 2108-2114.
115. Thompson PJ, Baxendale SA, Duncan JS, Sander JW Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000 ; 69 (5). 636-641.
116. Smith ME, Gevins A., McEvoy LK, et al. Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate. Epilepsia. 2006 ; 47 (4). 695-703.
117. Gallassi R., Morreale A., Lorusso S., et al. Cognitive effects of valproate. Epilepsy Res. 1990 ; 5 (2). 160-164.
118. Forsythe I., Butler R., Berg I., McGuire R. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol. 1991 ; 33 (6). 524-534.
119. Craig I., Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia. 1994 ; 35 (2). 381-390.
120. Hirsch E., Schmitz B., Carreño M. Epilepsy, antiepileptic drugs (AEDs) and cognition. Acta Neurol Scand Suppl. 2003 ; 180: 23-32.
121. Profenno LA, Jakimovich L., Holt CJ, et al. A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease. Curr Alzheimer Res. 2005 ; 2 (5). 553-558.
122. Gualtieri CT, Johnson LG Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium. MedGenMed. 2006 ; 8 (3). 46.
123. Klotz U., Avant GR, Hoyumpa A., et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975 ; 55 (2). 347-359.
124. Thompson TL, Moran MG, Nies AS Drug therapy: psychotropic drug use in the elderly (first of two parts). N Engl J Med. 1983 ; 308 (3). 134-138.
125. Castleden CM, George CF, Marcer D., Hallett C. Increased sensitivity to nitrazepam in old age. BMJ. 1977 ; 1 (6052). 10-12.
126. Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc. 2003 ; 51 (5). 671-677.
127. Paterniti S., Dufouil C., Bisserbe JC, Alpérovitch A. Anxiety, depression, psychotropic drug use and cognitive impairment. Psychol Med. 1999 ; 29 (2). 421-428.
128. Bedry R., Dartigues JF, Gagnon M., et al. The role of benzodiazepine consumption on negative functioning in elderly French community residents. J Clin Res Pharmacoepidemiol. 1990 ; 4: 135.
129. Dealberto MJ, Mcavay GJ, Seeman T., Berkman L. Psychotropic drug use and cognitive decline among older men and women. Int J Geriatr Psychiatry. 1997 ; 12 (5). 567-574.
130. Aranko K., Mattila MJ, Bordignon D. Psychomotor effects of alprazolam and diazepam during acute and subacute treatment, and during the follow-up phase. Acta Pharmacol Toxicol (Copenh). 1985 ; 56 (5). 364-372.
131. Moskowitz H., Smiley A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry. 1982 ; 43 (12, pt 2). 45-55.
132. Bond AJ, Lader MH Comparative effects of diazepam and buspirone on subjective feelings, psychological tests and the EEG. Int Pharmacopsychiatry. 1981 ; 16 (4). 212-220.
133. Spinweber CL, Johnson LC Effects of triazolam (0.5 mg) on sleep, performance, memory, and arousal threshold. Psychopharmacology (Berl). 1982 ; 76 (1). 5-12.
134. Bond A., Lader M. Correlations among measures of response to benzodiazepines in man. Pharmacol Biochem Behav. 1983 ; 18 (2). 295-298.
135. Erwin CW, Linnoila M., Hartwell J., et al. Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials. J Clin Psychopharmacol. 1986 ; 6 (4). 199-209.
136. Scharf MB, Fletcher K., Graham JP Comparative amnestic effects of benzodiazepine hypnotic agents. J Clin Psychiatry. 1988 ; 49 (4). 134-137.
137. Hommer DW, Matsuo V., Wolkowitz O., et al. Benzodiazepine sensitivity in normal human subjects. Arch Gen Psychiatry. 1986 ; 43 (6). 542-551.
138. Larson EB, Kukull WA, Buchner D., Reifler BV Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987 ; 107 (2). 169-173.
139. Lucki I., Rickels K., Geller AM Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology (Berl). 1986 ; 88 (4). 426-433.
140. Golombok S., Moodley P., Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med. 1988 ; 18 (2). 365-374.
141. Mamelak M., Csima A., Buck L., Price V. A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol. 1989 ; 9 (4). 260-267.
142. Woo E., Proulx SM, Greenblatt DJ Differential side effect profile of triazolam versus flurazepam in elderly patients undergoing rehabilitation therapy. J Clin Pharmacol. 1991 ; 31 (2). 168-173.
143. Tata PR, Rollings J., Collins M., et al. Lack of cognitive recovery following withdrawal from long-term benzodiazepine use. Psychol Med. 1994 ; 24 (1). 203-213.
144. Hanlon JT, Horner RD, Schmader KE, et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther. 1998 ; 64 (6). 684-692.
145. Lader MH, Curry S., Baker WJ Physiological and psychological effects of clorazepate in man. Br J Clin Pharmacol. 1980 ; 9 (1). 83-90.
146. Wittenborn JR, Flaherty CF, Hamilton LW, et al. The effect of minor tranquilizers on psychomotor performance. Psychopharmacology (Berl). 1976 ; 47 (3). 281-286.
147. Bond AJ, James DC, Lader MH Sedative effects on physiological and psychological measures in anxious patients. Psychol Med. 1974 ; 4 (4). 374-380.
148. Barrucand D. Benzodiazepines, alcohol and effects on vigilance [in French]. Encephale. 1983 ; 9 (4 )(suppl 2). 117B - 122B.
149. Moodley P., Golombok S., Lader M. Effects of clorazepate dipotassium and placebo on psychomotor skills. Percept Mot Skills. 1985 ; 61 (3, pt 2). 1121-1122.
150. Grasby PM, Friston KJ, Bench CJ, et al. The effect of apomorphine and buspirone on regional cerebral blood flow during the performance of a cognitive task-measuring neuromodulatory effects of psychotropic drugs in man. Eur J Neurosci. 1992 ; 4 (12). 1203-1212.
151. Grasby PM, Friston KJ, Bench C., et al. Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man. Psychopharmacology (Berl). 1992 ; 108 (3). 380-386.
152. Chamberlain SR, Müller U., Deakin JB, Corlett PR, Dowson J., Cardinal RN, et al. Lack of deleterious effects of buspirone on cognition in healthy male volunteers. J Psychopharmacol. 2007 ; 21 (2). 210-215.
153. Unrug-Neervoort A., van Luijtelaar G., Coenen A. Cognition and vigilance: differential effects of diazepam and buspirone on memory and psychomotor performance. Neuropsychobiology. 1992 ; 26 (3). 146-150.
154. Lader M. Psychological effects of buspirone. J Clin Psychiatry. 1982 ; 43 (12, pt 2). 62-68.
155. Mattila MJ, Aranko K., Seppala T. Acute effects of buspirone and alcohol on psychomotor skills. J Clin Psychiatry. 1982 ; 43 (12, pt 2). 56-61.
156. Seidel WF, Cohen SA, Bliwise NG, Dement WC Buspirone: an anxiolytic without sedative effect. Psychopharmacology (Berl). 1985 ; 87 (3). 371-373.
157. Boulenger JP, Squillace K., Simon P., et al. Buspirone and diazepam: comparison of subjective, psychomotor and biological effects. Neuropsychobiology. 1989 ; 22 (2). 83-89.
158. Schaffler K., Klausnitzer W. Placebo-controlled study on acute and subchronic effects of buspirone vs bromazepam utilizing psychomotor and cognitive assessments in healthy volunteers. Pharmacopsychiatry. 1989 ; 22 (1). 26-33.
159. Hart RP, Colenda CC, Hamer RM Effects of buspirone and alprazolam on the cognitive performance of normal elderly subjects. Am J Psychiatry. 1991 ; 148 (1). 73-77.
160. Ridout F., Shamsi Z., Meadows R., et al. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther. 2003 ; 25 (5). 1518-1538.
161. De Brabander A., Deberdt W. Effects of hydroxyzine on attention and memory in elderly subjects [in French]. Acta Psychiatr Belg. 1992 ; 92 (6). 370-382.
162. Karim A., Tolbert D., Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 ; 46 (2). 140-148.
163. Johnson MW, Suess PE, Griffiths RR Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006 ; 63 (10). 1149-1157.
164. Sanger DJ, Morel E., Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol. 1996 ; 313 (1-2). 35-42.
165. Ancoli-Israel S., Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry. 1999 ; 1 (4). 114-120.
166. Hedner J., Yaeche R., Emilien G.,, et al. Zaleplon Clinical Investigator Study Group. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. Int J Geriatr Psychiatry. 2000 ; 15 (8). 704-712.
167. Whitmore JN, Fischer JR, Barton EC, Storm WF Performance following a sudden awakening from daytime nap induced by zaleplon. Aviat Space Environ Med. 2004 ; 75 (1). 29-36.
168. Dooley M., Plosker GL Zaleplon: a review of its use in the treatment of insomnia. Drugs. 2000 ; 60 (2). 413-445.
169. Paul MA, Gray G., Kenny G., Pigeau RA Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med. 2003 ; 74 (12). 1263-1270.
170. Allain H., Monti J. General safety profile of zolpidem: safety in elderly, overdose and rebound effects. Eur Psychiatry. 1997 ; 12 (9). 21-29.
171. Holm KJ, Goa KL Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 ; 59 (4). 865-889.
172. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol. 1992 ; 43 (6). 597-601.
173. Scharf MB, Mayleben DW, Kaffeman M., et al. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry. 1991 ; 52 (2). 77-83.
174. Lobo BL, Greene WL Zolpidem: distinct from triazolam? Ann Pharmacother. 1997 ; 31 (5). 625-632.
175. Noble S., Langtry HD, Lamb HM Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs. 1998 ; 55 (2). 277-302.
176. Dehlin O., Rubin B., Rundgren A. Double-blind comparison of zopiclone and flunitrazepam in elderly insomniacs with special focus on residual effects. Curr Med Res Opin. 1995 ; 13 (6). 317-324.
177. Boyle J., Roach J., Schaefer K., et al. Next-day driving ability, cognition, and psychomotor function following nighttime administration of eszopiclone in primary insomniacs. Paper presented at: APA 2007 American Psychiatric Association 160th Annual Meeting ; May 19-24, 2007 ; San Diego, CA.
178. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc. 2002 ; 50 (5). 836-842.
179. Mintzer J., Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000 ; 93 (9). 457-462.
180. Tune L., Carr S., Hoag E., Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry. 1992 ; 149 (10). 1393-1394.
181. Lechevallier-Michel N., Fabrigoule C., Lafont S., et al. Normative data for the MMSE, the Benton visual retention test, the Isaacs's set test, the digit symbol substitution test and the Zazzo's cancellation task in subjects over the age 70: results from the PAQUID Study [in French]. Rev Neurol (Paris). 2004 ; 160 (11). 1059-1070.
182. Vangala VR, Tueth MJ Chronic anticholinergic toxicity: identification and management in older patients. Geriatrics. 2003 ; 58 (7). 36-37.
183. Bottiggi KA, Salazar JC, Yu L., et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry. 2006 ; 14 (11). 980-984.
184. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993 ; 3 (4). 335-348.
185. Kurlan R., Como P. Drug-induced alzheimerism. Arch Neurol. 1988 ; 45 (3). 356-357.
186. de Smet Y., Ruberg M., Serdaru M., et al. Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1982 ; 45 (12). 1161-1164.
187. Zemishlany Z., Thorne AE Anticholinergic challenge and cognitive functions: a comparison between young and elderly normal subjects. Isr J Psychiatry Relat Sci. 1991 ; 28 (3). 32-41.
188. Little JT, Johnson DN, Minichiello M., et al. Combined nicotinic and muscarinic blockade in elderly normal volunteers: cognitive, behavioral, and physiologic responses. Neuropsychopharmacology. 1998 ; 19 (1). 60-69.
189. Dumas J., Hancur-Bucci C., Naylor M., et al. Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women. Neuropsychopharmacology. 2006 ; 31 (9). 2065-2078.
190. Rabey JM, Neufeld MY, Treves TA, et al. Cognitive effects of scopolamine in dementia. J Neural Transm. 1996 ; 103 (7). 873-881.
191. Sadeh M., Braham J., Modan M. Effects of anticholinergic drugs on memory in Parkinson's disease. Arch Neurol. 1982 ; 39 (10). 666-667.
192. Minzenberg MJ, Poole JH, Benton C., Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004 ; 161 (1). 116-124.
193. Lechevallier-Michel N., Molimard M., Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol. 2005 ; 59 (2). 143-151.
194. Gelenberg AJ, Van Putten T, Lavori PW, et al. Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol. 1989 ; 9 (3). 180-185.
195. Drimer T., Shahal B., Barak Y. Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. Int Clin Psychopharmacol. 2004 ; 19 (1). 27-29.
196. Bartus RT, Dean RL, Beer B., Lippa AS The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982 ; 217 (4558). 408-414.
197. Molchan SE, Martinez RA, Hill JL, et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev. 1992 ; 17 (3). 215-226.
198. Basu R., Dodge H., Stoehr GP, Ganguli M. Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: effects on cognition. Am J Geriatr Psychiatry. 2003 ; 11 (2). 205-213.
199. Kay GG, Berman B., Mockoviak SH, et al. Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch Intern Med. 1997 ; 157 (20). 2350-2356.
200. Burns M., Moskowitz H. Effects of diphenhydramine and alcohol on skills performance. Eur J Clin Pharmacol. 1980 ; 17 (4). 259-266.
201. Gengo FM, Gabos C., Mechtler L. Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator. Ann Allergy. 1990 ; 64 (6). 520-526.
202. Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med. 2000 ; 132 (5). 354-363.
203. Tejera CA, Saravay SM, Goldman E., Gluck L. Diphenhydramine-induced delirium in elderly hospitalized patients with mild dementia. Psychosomatics. 1994 ; 35 (4). 399-402.
204. Sands L., Katz IR, DiFilippo S., et al. Identification of drug-related cognitive impairment in older individuals: challenge studies with diphenhydramine. Am J Geriatr Psychiatry. 1997 ; 5 (2). 156-166.
205. Lines C., Traub M., Raskin S., et al. Lack of sedative and cognitive effects of diphenhydramine and cyclobenzaprine in elderly volunteers. J Psychopharmacol. 1997 ; 11 (4). 325-329.
206. Katz IR, Sands LP, Bilker W., et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998 ; 46 (1). 8-13.
207. Berlinger WG, Goldberg MJ, Spector R., et al. Diphenhydramine: kinetics and psychomotor effects in elderly women. Clin Pharmacol Ther. 1982 ; 32 (3). 387-391.
208. Tharion WJ, McMenemy DJ, Rauch TM Antihistamine effects on the central nervous system, cognitive performance and subjective states. Neuropsychobiology. 1994 ; 29 (2). 97-104.
209. Zachariah E., Kumari V., Galea A., et al. Effects of oral procyclidine administration on cognitive functions in healthy subjects: implications for schizophrenia. J Clin Psychopharmacol. 2002 ; 22 (2). 224-226.
210. Nishiyama K., Momose T., Sugishita M., Sakuta M. Positron emission tomography of reversible intellectual impairment induced by long-term anticholinergic therapy. J Neurol Sci. 1995 ; 132 (1). 89-92.
211. Heinik J. Effects of trihexyphenidyl on MMSE and CAMCOG scores of medicated elderly patients with schizophrenia. Int Psychogeriatr. 1998 ; 10 (1). 103-108.
212. Fleminger S., Greenwood RJ, Oliver DL Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev. 2006 ;(4). 63G - 65G, CD003299.
213. Kornischka J., Cordes J., Agelink MW 40 Years β-adrenoceptor blockers in psychiatry [in German]. Fortschr Neurol Psychiatr. 2007 ; 75 (4). 199-210.
214. Applegate WB, Phillips HL, Schnaper H., et al. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med. 1991 ; 151 (9). 1817-1823.
215. Goldstein S. Effect of beta-adrenergic blocking agents on the circadian occurrence of ischemic cardiovascular events. Am J Cardiol. 1990 ; 66 (16). 63G - 65G.
216. McAinsh J., Cruickshank JM β-Blockers and central nervous system side effects. Pharmacol Ther. 1990 ; 46 (2). 163-197.
217. Prince MJ, Bird AS, Blizard RA, Mann AH Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ. 1996 ; 312 (7034). 801-805.
218. Koella WP CNS-related (side-)effects of β-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol. 1985 ; 28 (suppl): 55-63.
219. Prince M., Lewis G., Bird A., et al. A longitudinal study of factors predicting change in cognitive test scores over time, in an older hypertensive population. Psychol Med. 1996 ; 26 (3). 555-568.
220. Applegate WB, Pressel S., Wittes J., et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the Systolic Hypertension in the Elderly Program. Arch Intern Med. 1994 ; 154 (19). 2154-2160.
221. Rogers TK, Bowman CE Cognitive impairment associated with β-blockade in the elderly. Postgrad Med J. 1990 ; 66 (782). 1050-1052.